Day: November 6, 2023

Company delivers another strong quarterly gross margin with further expansion Reaffirms EBITDA guidance; adjusts full year revenue and railcar delivery guidance down CHICAGO, Nov. 06, 2023 (GLOBE NEWSWIRE) — FreightCar America, Inc. (NASDAQ: RAIL) (“FreightCar America” or the “Company”), a diversified manufacturer of railroad freight cars, today reported results for the third quarter ended September 30, 2023. Third Quarter 2023 HighlightsRevenues of $61.9 million on 503 railcar deliveries, a decrease of 27.8% compared to revenues of $85.7 million on 783 railcar deliveries in the third quarter of 2022 Gross margin of 14.9% with gross profit of $9.2 million, compared to gross margin of 5.3% with gross profit of $4.6 million in the third quarter of 2022 Net income of $3.2 million, or ($0.03) per share and Adjusted Net income of...

HOUSTON, Nov. 06, 2023 (GLOBE NEWSWIRE) — Par Pacific Holdings, Inc. (NYSE: PARR) (“Par Pacific” or the “Company”) today reported its financial results for the quarter ended September 30, 2023.Net Income of $171.4 million, or $2.79 per diluted share Adjusted Net Income of $193.5 million, or $3.15 per diluted share Record Adjusted EBITDA of $255.7 millionPar Pacific reported net income of $171.4 million, or $2.79 per diluted share, for the quarter ended September 30, 2023, compared to $267.4 million, or $4.47 per diluted share, for the same quarter in 2022. Third quarter 2023 Adjusted Net Income was $193.5 million, compared to $172.0 million in the third quarter of 2022. Third quarter 2023 Adjusted EBITDA was $255.7 million, compared to $214.1 million in the third quarter of 2022. A reconciliation of reported non-GAAP financial...

-Advisory Committee meeting for exagamglogene autotemcel (exa-cel) for the treatment of severe sickle cell disease (SCD) completed October 31, 2023; exa-cel assigned Prescription Drug User Fee Act (PDUFA) target action date of December 8, 2023 for SCD- -Exa-cel assigned PDUFA target action date of March 30, 2024 for transfusion-dependent beta thalassemia (TDT)- -Clinical trials ongoing for our CAR T product candidates, CTX110® and CTX112™, targeting CD19 in B-cell malignancies- -Clinical trials ongoing for our CAR T product candidates, CTX130™ and CTX131™, targeting CD70 in T cell malignancies and solid tumors- -Clinical trial ongoing for VCTX211™, an allogeneic, gene-edited, stem cell derived product candidate for the treatment of Type 1 Diabetes (T1D)- -Clinical trial initiated for CTX310™, targeting...

Received $399M DOE LPO Title VXII loan conditional commitment, shipped first Eos Z3™ customer energy storage system, and provided an update to its 2023 outlook EDISON, N.J., Nov. 06, 2023 (GLOBE NEWSWIRE) — Eos Energy Enterprises, Inc. (NASDAQ: EOSE) (“Eos” or the “Company”), a leading provider of safe, scalable, efficient, and sustainable zinc-based long duration energy storage systems, today announced financial results for the third quarter ended September 30, 2023. Key HighlightsRevenue totaled $0.7 million, compared to $6.1 million in 3Q 2022, as the Company began commercial production and shipped the first Eos Z3 energy storage systems. $21.3 million Cost of Goods Sold, a 57% year over year decrease, driven by lower volume partially offset by one-time non-cash accounting adjustments for project commissioning...

HAMILTON, BERMUDA, November 6, 2023 – DHT Holdings, Inc. (NYSE:DHT) (“DHT” or the “Company”) today announced its results for the quarter ended September 30, 2023.The full report is available here and in the below attachment. About DHT Holdings, Inc.DHT is an independent crude oil tanker company. Our fleet trades internationally and consists of crude oil tankers in the VLCC segment. We operate through our integrated management companies in Monaco, Norway, Singapore, and India. You may recognize us by our renowned business approach as an experienced organization with focus on first rate operations and customer service; our quality ships; our prudent capital structure that promotes staying power through the business cycles; our combination of market exposure and fixed income contracts for our fleet; our counter cyclical philosophy with respect...

EINDHOVEN, The Netherlands, Nov. 06, 2023 (GLOBE NEWSWIRE) — NXP Semiconductors N.V. (NASDAQ: NXPI) today reported financial results for the third quarter, ended October 1, 2023. “NXP delivered quarterly revenue of $3.43 billion, $34 million above the midpoint of guidance. Revenue trends in our Mobile, Industrial & IoT and Automotive end-markets all performed in-line or better than anticipated, while our Communication Infrastructure & Other end market was slightly below our expectations. The combination of our third quarter results, and the mid-point of our fourth quarter guidance indicates revenue for the full year 2023 will be flat versus 2022 in a challenging and cyclical market environment,” said Kurt Sievers, NXP President and Chief Executive Officer. Key Highlights for the Third Quarter 2023:Revenue was $3.43...

Presented initial Phase 1b data for ORIC-114 in patients with EGFR and HER2 Exon 20 mutated NSCLC demonstrating potential best-in-class profile Initial Phase 1b data for ORIC-533 in patients with multiple myeloma to be presented at the 65th ASH Annual Meeting being held December 9-12, 2023 Initial Phase 1b data for ORIC-944 in patients with prostate cancer expected in first quarter of 2024 Cash and investments of $256.2 million expected to fund operating plan into late 2025 SOUTH SAN FRANCISCO and SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today reported financial results and operational updates for the quarter ended September 30, 2023. “We continued making strong progress...

– Affirms Full Year 2023 Guidance – GREAT NECK, N.Y., Nov. 06, 2023 (GLOBE NEWSWIRE) — BRT APARTMENTS CORP. (NYSE: BRT), a real estate investment trust that owns, operates, and, to a lesser extent, holds interests in joint ventures that own multi-family properties, today reported results for the third quarter ended September 30, 2023. HighlightsReported results for the third quarter of 2023 of net loss of $1.5 million, or $(0.08) per diluted share, Funds from Operations, or FFO, of $0.31 per diluted share and Adjusted Funds from Operations, or AFFO, of $0.41 per diluted share. Equity in earnings of unconsolidated joint ventures was $426,000 in the third quarter of 2023 and $135,000 for the corresponding 2022 quarter. Combined Portfolio NOI decreased 0.4% for the third quarter when compared with the prior-year period. Repurchased...

— Rental Income Grew 4.7% Year-over-Year — — Repurchases $2.5 Million of Shares Subsequent to Quarter End and $9.1 Million in 2023 — GREAT NECK, N.Y., Nov. 06, 2023 (GLOBE NEWSWIRE) — One Liberty Properties, Inc. (NYSE: OLP), a real estate investment trust focused on net leased properties, today announced operating results for the quarter ended September 30, 2023. “We are pleased that our efforts to transform our portfolio towards industrial ownership is producing the growth we had anticipated. This is marked by our second consecutive quarter of year-over-year rental income growth of over 4%. We also grew operating cashflow in the third quarter over the same prior year quarter,” stated Patrick J. Callan, Jr., President and Chief Executive Officer of One Liberty. “We are proud that we have produced these positive accomplishments...

Annual guidance increased to $136 million – $137 million, implying annual growth of 28%-29% SANTA CLARA, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) — SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended September 30, 2023. Recent Financial HighlightsRecord worldwide revenue of $34.0 million for the third quarter 2023, representing approximately 29% growth over the corresponding period in 2022 Record U.S. revenue of $32.3 million for the third quarter 2023, representing approximately 31% growth over the corresponding period in 2022 Gross margin of approximately 79% for the third quarter 2023 Over 1,040 U.S. active surgeons in the third quarter 2023, representing approximately 30% growth over the...